Monitor the outcome of the Type D FDA meeting in August 2026 for clarity on the registrational path. The year-end 2026 Part A tumor response data will be the next key catalyst. Until then, the stock is likely to trade on trial execution milestones and broader biotech sentiment.
Drug in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $0.9289entry
- T+1 · 4mo ago −2.23%α −2.58% · $0.9082
- T+5 · 4mo ago −8.14%α −7.35% · $0.8533
- T+20 · 3mo ago −13.58%α −16.76% · $0.8028
- T+60 · 6w ago −35.62%α −39.62% · $0.5980
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, reporting that half of planned clinical sites will be activated by end of July with over 20 patients pre-identified. The company will hold a Type D meeting with the FDA in early August 2026 to discuss adding a registrational Part B to the study, which could support accelerated and full approval. Initial tumor response data from Part A is expected by year-end 2026, with Part B enrollment potentially starting Q1 2027.
Key Facts
- Half of planned clinical sites for REO 033 will be activated by end of July 2026; over 20 patients pre-identified across centers.
- Type D meeting with FDA scheduled for first half of August 2026 to discuss registrational expansion via Part B of REO 033.
- Part B designed as a randomized study with blinded independent central review to support potential accelerated and full approval.
- Initial tumor response update from Part A expected by year-end 2026; Part B enrollment targeted for Q1 2027 subject to FDA feedback.
- Pelareorep has Fast Track designation from FDA for colorectal cancer indication.
Financial Impact
No financial figures reported; filing is a clinical and regulatory update with no revenue or cost disclosures.
Risk Factors
- FDA may not agree to the proposed registrational design, delaying or altering the pathway.
- Clinical trial enrollment or data may disappoint, particularly given the challenging RAS-mutant MSS CRC indication.
- Company is pre-revenue and may require additional financing to complete the expanded study.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000043 |
| Document: oncolyticsreo033update.htm | 0001129928-26-000043 |
| Document: 0001129928-26-000043-index-headers.html | 0001129928-26-000043 |
| Document: 0001129928-26-000043-index.html | 0001129928-26-000043 |
| Document: 0001129928-26-000043.txt | 0001129928-26-000043 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers